PAVmed Inc. — Director's Dealing 2017

Sep 7, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PAVmed Inc. (PAVM)
CIK: 0001624326
Period of Report: 2017-09-05

Reporting Person: Aklog Lishan (Director, Chairman and CEO, 10% Owner)
Reporting Person: HCFP/Capital Partners III LLC (10% Owner)
Reporting Person: Pavilion Venture Partners LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-09-05	Common Stock	P	800	—	Acquired	63289	Direct
2017-09-06	Common Stock	P	899	—	Acquired	64188	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-09-05	Warrants	$5.00	P	100	Acquired	2022-01-29	Common Stock (100)	Direct
2017-09-05	Warrants	$5.00	P	100	Acquired	2022-01-29	Common Stock (100)	Direct
2017-09-06	Warrants	$5.00	P	800	Acquired	2022-01-29	Common Stock (800)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	285	Indirect
Common Stock	300	Indirect
Common Stock	5713879	Indirect
Common Stock	2520532	Indirect
Common Stock	87020	Indirect
Common Stock	125000	Indirect
Common Stock	20000	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants	$5.00	2022-01-29	Common Stock (5713879)	5713879	Indirect
Warrants	$5.00	2022-01-29	Common Stock (2220532)	2220532	Indirect
Warrants	$5.00	2022-01-29	Common Stock (387020)	387020	Indirect
Warrants	$5.00	2022-01-29	Common Stock (125000)	125000	Indirect
Warrants	$5.00	2022-01-29	Common Stock (20000)	2000	Indirect

Footnotes

F1: The shares were purchased at a weighted average price of approximately $4.73875 per share. These shares were purchased in multiple transactions at prices ranging from $4.50 to $4.99, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.

F2: The shares were purchased at a weighted average price of approximately $4.8544493882 per share. These shares were purchased in multiple transactions at prices ranging from $4.75 to $4.99, inclusive. The reporting person undertakes to provide to PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth this footnote to this Form 4.

F3: The warrants were purchased at a weighted average price of approximately $1.20625 per warrant. These warrants were purchased in multiple transactions at prices ranging from $1.15 to $1.35, inclusive. The reporting person undertakes to provide PAVmed Inc., any security holder of PAVmed Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of warrants purchased at each separate price within the ranges set forth this footnote to this Form 4.

F4: Dr. Aklog is a member and a co-manager of HCFP/Capital Partners III LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F5: Dr. Aklog is a member and sole manager of Pavilion Venture Partners LLC, and has sole voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F6: Dr. Aklog is a controlling shareholder of HCFP Inc., and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his proportionate pecuniary interest therein.

F7: Dr. Aklog is a member and a co-manager of the entity that acts as sole manager of HCFP/Capital Partners IIIB LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.

F8: Dr. Aklog is a co-manager of HCFP/AG LLC, and shares joint voting and dispositive power over the shares held by this entity. Dr. Aklog disclaims beneficial ownership of shares held by this entity, except to the extent of his pecuniary interest therein.